20 June 2012
The NANOGENOTOX fourth General Assembly meeting took place in Brussels (Belgium) and was hosted by the Institute of Public Health ( IPH, Belgium) on May 2 to 4, 2012. All the partners of the Joint Action were present.
The first day started with WP1 (Coordination) presenting the JA
’s finances for the second year as well as the reporting requirements for the second interim implementation report, to be submitted to the Executive Agency for Health and Consumers ( EAHC
). Then WP4 (Characterisation) presented its results. WP4 finalized the primary physico-chemical characterization of the NANOGENOTOX test materials and started to prepare their final deliverable reports. As part of the final work analysis of vial-to-vial and intra/vial sample homogeneity was completed (using TEM
, XRD, DLS
and TGA analysis). The status and results on TiO2 and SiO2 have been shared with the OECD
WPMN Sponsorship programme. The first scientific paper has been published and two additional papers are under review.
In the afternoon, WP2 (Dissemination) presented an update of the tools available for the dissemination of the project and its results tools that are continuously improved. Some partners presented communications during scientific meetings and most of these communications were uploaded on the website. A discussion time was then set up within WP7 (Toxicokinetic and biodistribution) and the partners discussed the work progress and exchanged ideas regarding the methodologies applied and results obtained. Two break-out sessions followed this discussion one for WP7 partners only, and another one for WP3 with the members of the internal evaluation team.
The morning of the second day was dedicated to the WP5 (in vitro genotoxicity
testing). In this workpackage, partners needed to agree on the protocols for the Round Robin test
, based on the results from comet and micronucleus assay that were obtained during the first phase of WP5.
In the afternoon, all the partners of the JA were present at the Stakeholders
The third day started with some presentations of the work done in WP6 (in vivo genotoxicity testing): training for the partners to share their experience and choice of the positive controls to be used in the experiments. This session was followed by a discussion between the partners in order to clarify the methodology to be applied in WP6 for the coming months. In the afternoon, each scientific WP leader presented an update of the WP’s work progress as well as a feedback of the different discussions that occurred during this General Assembly meeting.
The GA ended on may 4, 2012 and the next NANOGENOTOX General Assembly should be held on October 10 to 12 2012, in Lisbon (Portugal), hosted by the National Health Institute Doutor Ricardo Jorge ( INSA).
We would like to thank the IPH who kindly hosted this meeting, making this event very successful as well as all the partners for their participation!